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Abstract 
 
The most common causes of microcytosis are iron deficiency anemia (IDA) and Beta 
thalassemia trait (BTT). BTT is an important differential diagnosis of IDA in 
Southeast Asian countries including Bangladesh. A definitive diagnosis of BTT and 
IDA is based on the result of capillary electrophoresis and serum iron profiles. BTT 
often shows microcytosis, a normal or an increased red blood cell (RBC) count, and 
an elevated level of HbA2, which provide the basis for laboratory screening and 
diagnosis of IDA was made on the basis of decreased ferritin values. 
The purpose of this study was to explore the use of different red cell parameters with 
(RET – He) in diagnosis  of BTT & IDA.  
 
A total of 210 samples were obtained from specimen reception unit of Icddr,b 
irrespective of  sex. Complete blood count was performed to all individuals. 
Hemoglobin electrophoresis and serum ferritin was performed to samples with MCV 
less than 80 fl. 
 
Prevalence of BTT in this study was 16%, whereas IDA represented 16.6% of total 
210 samples investigated. The lowest MCV values were seen in BTT compared with 
the IDA group. Red blood cell distribution width (RDW-CV) was the highest in IDA 
group followed by BTT group and then control group. Elevated RBCs count were 
seen in BTT than in IDA and normal group. A reduction in reticulocyte hemoglobin 
has been observed in other conditions besides iron deficiency, such as in thalassemia.  
 
Microcytosis accompanied by a high RBC count, normal RDW and an elevated level 
of HbA2 is suggestive of BTT. Microcytosis accompanied by a low ferritin value 
suggests iron deficiency. Besides measurement of the reticulocyte hemoglobin (RET-
He) content is helpful in detecting early stages of iron deficiency prior to the 
development of anemia. 
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1.1 Introduction 
The most commonly encountered disorders with mild microcytic anemia are iron 
deficiency anemia (IDA) and beta thalassemia trait (BTT). Other diagnoses to 
consider include anemia of chronic disease, lead toxicity and sideroblastic anemia. 
 
Thalassemia is one of the major autosomal recessive hereditary hemoglobinopathies  
prevalent in the world population, particularly in Mediterranean belt, Far-eastern and 
South East Asian countries 1. Thalassemias are a group of hemoglobinopathy caused 
by genetic mutations of the hemoglobin (Hb) genes, resulting in reduced production 
or total absence of one or more globin chains2. Thalassemia consists of two main 
classes, alpha thalassemia and beta thalassemia by their clinical manifestations  and 
genetic background3.  
 Beta thalassemia is the most frequent type of thalassemia which can be classified 
further into three forms: β thalassemia major, β thalassemia intermediate and β 
thalassemia minor/β thalassemia trait 4. β-thalassemia major is commonly caused by 
homozygous deletion of the β-globin chain gene. It is clinically characterized by 
lifelong severe hemolytic anemia that eventually affects many organs and is 
associated with high morbidity and mortality1. Intermediate β thalassaemic 
individuals carry mutation in one or both of the β globin genes. β-thalassemia minor 
or β-thalassemia trait (BTT) is the heterozygous form. Most patients are 
asymptomatic and some patients have only mild anaemia5. Thalassemia occurs more 
often among certain ethnicities, including people of Italian, Greek, Middle Eastern, 
Asian and African decent6.  
 
In developing countries like Bangladesh where resources are limited, thalassemia is a 
major health burden. According to Bangladesh Thalassemia foundation, about 7% of 
the Bangladeshi population are thalassemia carriers which equals >10 million people 
and each year 7000 new babies born with thalassemia. BTT often shows microcytosis, 
a normal or an increased red blood cell (RBC) count, and an elevated level of HbA2, 
which provide the basis for laboratory screening 5. HbA2 is a normal Hb variant 
consisting of 2α chains and 2δ chains. HbA2 has a function similar to that of HbA. 
1. Introduction 
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The percentage of HbA2 varies depending on the assay but generally is in the range of 
1.5-3.5%2. The majority of patients with BTT show elevated HbA2 level and some 
authors have used an HbA2 level of more than 4% to diagnose BTT 
7. 
 
Iron deficiency anaemia is the most common microcytic hypochromic anemia 
worldwide. Anemia resulting from lack of sufficient iron to synthesize hemoglobin is 
the most common hematological disease in  young children and women of 
reproductive age but it can be found in people of any age-group8.  It has been 
estimated that 30% of the global population suffers from iron deficiency anemia 
(IDA) and most of those affected live in the developing countries like Bangladesh9. 
Iron deficiency anemia in adults is caused by loss of blood, while in childhood faulty 
diet is to blame. It is a severe stage of iron shortage in which haemoglobin (or 
haematocrit) falls below the normal range. There is no hemolysis, erythrocytes 
survive normally and serum iron level tends to be low10. 
 
Iron deficiency modulates the synthesis of HbA2, resulting in reduced HbA2 levels in 
patients with IDA11. Affected individuals show RBC morphological change of 
microcytosis, hypochromia, anisocytosis, and poikilocytosis. Percentage of 
hypochromic red cells may be high before the anemia develops. It is found that a 
reduction in Hb concentration is a late feature of iron deficiency 12. 
 
Accelerated development, hormonal changes, malnutrition, and starting of menstrual 
periods in girls are the major causes of iron-deficiency anaemia during adolescence, 
which may also lead to impaired perception and learning difficulties 13. The 
detrimental effects of anaemia on work productivity of adults and physical 
development of children are of major concern14. 
 
BTT is an important differential diagnosis of iron deficiency anemia (IDA). 
Thalassemia minor  is an important hematologic condition because while the 
conditions observed in study of the blood may closely mimic those that are present in 
iron deficiency anemia, the therapy is radically different10. It is very important not to 
treat a patient with thalassemia with an iron supplement as this can lead to 
hemochromatosis (accumulation of iron in various organs, specially the liver). Thus 
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reliable and efficient diagnostic ways to distinguish between thalassemic and iron 
restricted microcytic hypochromic anemia are desirable.  
 
1.2 Microcytic hypochromic anemia 
1.2.1 Microcytosis 
Microcytosis is usually encountered incidentally when a complete blood count (CBC) 
is performed for various reasons. The condition is defined as a mean corpuscular 
volume of less than 80 μm3 (80 fL) in adults and is often associated with anemia15.   
 
 
 
 
 
           Figure1.1: Microcytic hypochromic anaemia in contrast to normal blood smear 
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Differential diagnosis: 16, 17 
The most common causes of microcytosis are iron deficiency anemia and thalassemia 
trait.  
Table 1.1 
Differential Diagnosis of Microcytosis 
Children and adolescents Menstruating women 
Men and non 
menstruating women 
 Iron deficiency 
anemia 
 Thalassemia trait 
 Other hemo-
globinopathies 
 Lead toxicity 
 Chronic 
inflammation 
 Sideroblastic 
anemia 
 Iron deficiency 
anemia 
 Thalassemia trait 
 Pregnancy 
 Anemia of chronic 
disease 
 Sideroblastic 
anemia 
 Iron 
deficiency 
anemia 
 Anemia of 
chronic 
disease 
 Thalassemia trait 
 
Note: Listed in descending order of frequency 
1.2.2 Specific causes of Microcytosis 
1.2.2.1 Iron deficiency anemia 
In Bangladesh, nutritional anaemia has long been identified as a serious public-health 
problem 18. Moreover, many surveys conducted in the past stated that anaemia is a 
severe problem among all across age, population and geographic groups in 
Bangladesh. In 2004, another survey conducted by Nutritional Surveillance Project of 
Helen Keller International in collaboration with the Institute of  Public Health 
Nutrition showed that 68% of under-five children were anaemic. The survey also 
 15 
 
suggested that 40% of adolescent girls and 31% adolescent boys as well as 46% of 
non-pregnant and 39% of pregnant women were affected by anemia.19 
Iron deficiency anemia occurs when the absorption of iron through dietary intake does 
not match the needs of the body. The mismatch occurs from inadequate dietary intake 
or increased needs, which usually cause only mild anemia or from blood loss or 
malabsorption, which can lead to more significant anemia.15 
Causes of iron deficiency anemia20:  
 Iron deficiency is the most common cause of anemia. There are many reasons why a 
person might become deficient in iron. These include: 
 
a) Inadequate iron intake 
Eating too little iron over an extended amount of time can cause a shortage in your 
body. Foods such as meat, eggs, and some green leafy vegetables are high in iron. 
Because iron is essential during times of rapid growth and development, pregnant 
women and young children may need even more iron-rich foods in their diet. 
b)  Blood loss due to menstruation 
In women of childbearing age, the most common causes of iron deficiency anemia 
are heavy menstrual bleeding and blood loss during childbirth. 
c) Internal bleeding 
Certain medical conditions can cause internal bleeding, which can lead to iron 
deficiency anemia. Examples include an ulcer in stomach, polyps (tissue growths) 
in the colon or intestines, or colon cancer. Regular use of pain relievers, such as 
aspirin, can also cause bleeding in the stomach.  
d)  Inability to absorb iron 
Certain disorders or surgeries that affect the intestines can also interfere with how 
body absorbs iron. Even not intake of enough iron in diet, celiac disease or 
intestinal surgery, such as gastric bypass, may limit the amount of iron body can 
absorb. 
 
 
 16 
 
Risk group for iron deficiency anemia21:  
 
Iron deficiency anemia is a common condition and can occur in both men and women 
of any age and from any ethnic group. Some people may be at greater risk for iron 
deficiency anemia than others. These include: 
 women of childbearing age or pregnant women 
 people with poor diets 
 people who donate blood frequently 
 infants and children, especially those born prematurely or experiencing a 
growth spurt 
 vegetarians who don’t replace meat with another iron-rich food 
 
Complications21: 
Mild iron deficiency anemia usually doesn't cause complications. However, left 
untreated, iron deficiency anemia can become severe and lead to health problems, 
including the following: 
1. Heart problems: Iron deficiency anemia may lead to a rapid or irregular 
heartbeat. Heart must pump more blood to compensate for the lack of 
oxygen carried in  blood when anemia occurs. This can lead to an enlarged 
heart or heart failure. 
2. Problems during pregnancy:  In pregnant women, severe iron deficiency 
anemia has been linked to premature births and low birth weight babies. 
But the condition is preventable in pregnant women who receive iron 
supplements as part of their prenatal care. 
3.  Growth problems:  In infants and children, severe iron deficiency can             
lead to anemia as well as delayed growth and development.  
Treatment of IDA21: 
 
Doctors normally treat the condition with iron supplements or changes to diet. 
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1.2.2.2  Thalassemia 
Thalassemia is a major health problem, placing an immeasurable emotional, 
psychological 
and economic burden on millions of people around the World22. Thalassemia, also 
called Mediterranean anemia, is a form of inherited autosomal recessive blood 
disorder characterized by abnormal formation of hemoglobin.23 
Mutation in the genes encoding alpha chain and beta chain of hemoglobin are the 
primary cause of thalassemia resulting in the absence or inadequate synthesis of one 
of the globin chains. This anomaly in synthesis of globin chain can cause to the 
premature destruction of Red Blood Cells (RBCs), thus causing anaemia and other 
secondary effects, the typical symptoms of thalassemia.23 
 
 
 
               Figure 1.2 : Thalassemia has an autosomal recessive pattern of inheritance. 
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Pathophysiology24: 
Normally, the majority of adult hemoglobin (HbA) is composed of four protein 
chains, two α and two β globin chains arranged into a heterotetramer. In thalassemia, 
patients have defects in either the α or β globin chain, causing production of abnormal 
red blood cells . 
The thalassemias are classified according to which chain of the hemoglobin molecule 
is affected. In α-thalassemias, production of the α globin chain is affected, while in β-
thalassemia, production of the β globin chain is affected. 
The β globin chains are encoded by a single gene on chromosome 11; α globin chains 
are encoded by two closely linked genes on chromosome 16. Thus, in a normal person 
with two copies of each chromosome, two loci encode the β chain, and four loci 
encode the α chain.   
Epidemiology: 
The beta form of thalassemia is particularly prevalent among  Mediterranean peoples 
and this geographical association is responsible for its naming.25Thalassemia resulted 
in 25,000 deaths in 2013 down from 36,000 deaths in 1990.26 
In Europe, the highest concentrations of the disease are found in Greece, coastal 
regions in Turkey (particularly the Aegean Region such as Izmir, Balikesir, Aydin, 
Mugla, and   Mediterranean Region such as Antalya, Adana, Mersin), in parts of Italy, 
particularly southern Italy and the lower Po valley. The major Mediterranean islands 
(except the Balearics) such as Sicily, Sardinia, Malta, Corsica, Cyprus, and Crete are 
heavily affected in particular. Other Mediterranean people, as well as those in the 
vicinity of the Mediterranean, also have high rates of thalassemia, including people 
from West Asia and North Africa. Far from the Mediterranean, South Asians are also 
affected, with the world's highest concentration of carriers (16% of the population) 
being in the Maldives. 
Nowadays, it is found in populations living in Africa, the Americas, and in Tharu 
people in the Terai region of Nepal and India.27 It is believed to account for much 
lower malaria sicknesses and deaths,28 accounting for the historic ability of Tharus to 
survive in areas with heavy malaria infestation, where others could not. Thalassemias 
are particularly associated with people of Mediterranean origin, Arabs 
(especially Palestinians and people of Palestinian descent), and Asians.29 The 
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Maldives has the highest incidence of Thalassemia in the world with a carrier rate of 
18% of the population. The estimated prevalence is 16% in people from Cyprus, 
1%30 in Thailand, and 3–8% in population  from Bangladesh,China,India,Malaysia 
and Pakistan. Thalassemias also occur in descendants of people fromLatin 
America and Mediterranean countries (e.g. Greece, Italy, Portugal, Spain, and others). 
Classification of thalassemia: 31 
A) Alpha Thalassemia 
People whose hemoglobin does not produce enough alpha protein have alpha 
thalassemia. It is commonly found in Africa, the Middle East, India, Southeast Asia, 
southern China, and 
occasionallythe Mediterranean region. 
Types of Alpha Thalassemia32 
Alpha globin is made by four genes and one or more can be mutated or missing, so 
there are four kinds of alpha thalassemia: 
a) One missing or abnormal gene makes a child a silent alpha thalassemia carrier. 
Silent alpha thalassemia carriers have no signs or symptoms of the disease, but 
are able to pass thalassemia on to their children. 
b) Two missing or mutated genes is a condition called alpha thalassemia minor or 
having alpha thalassemia trait. Children with this condition may have red 
blood cells that are smaller than normal (microcytosis) and sometimes very 
slight anemia. People with alpha thalassemia minor usually don't have any 
symptoms at all, but can pass thalassemia on to their children. The two 
abnormal genes can be on the same chromosome (called the cis position) or 
one on each chromosome (called the transposition). If two genes on the same 
chromosome are affected, the person can pass along a two-gene defect to his 
or her child. This situation is much more common in people of Asian descent. 
c) Three missing or mutated genes is called hemoglobin H disease. Signs and 
symptoms will be moderate to severe. 
d) Four missing or mutated genes is a condition known as alpha thalassemia 
major or hydrops fetalis. This almost always leads to a fetus dying before 
 20 
 
delivery or a newborn baby dying shortly after birth. However if this disease is 
suspected because of a history in the family, it can be diagnosed prenatally. 
Sometimes, if treatment is initiated before the baby is even born, the baby can 
survive. 
 
B) Beta-thalassemia31 
Beta-thalassemia is an autosomal recessive genetic condition in which the normal beta 
globin chains that make up hemoglobin are underproduced.  It is found in people of 
Mediterranean descent, such as Italians and Greeks, and is also found in the Arabian 
Peninsula, Iran, Africa,Southeast Asia and southern China. 
Types of Beta Thalassemia31:  
There are three types of beta thalassemia that also range from mild to severe in their 
effect on the body. 
 
a) Thalassemia Trait:  
Beta-thalassemia trait is the heterozygous form of the disease. Individuals 
who have one abnormal beta globin gene have beta thalassemia trait (also 
known as beta thalassemia minor). In this condition, the lack of beta 
protein is not great enough to cause problems in the normal functioning of 
the hemoglobin. A person with this condition simply carries the genetic 
trait for thalassemia and will usually experience no health problems other 
than a possible mild to moderate microcytic anemia. In addition, the mean 
corpuscular volume can sometimes reach much lower levels than with iron 
deficiency anemia alone. The red blood cell count can help differentiate  
BTT and IDA because it is often in the high to normal range with beta-
thalassemia trait. Ultimately, the diagnosis of beta-thalassemia trait is 
made when hemoglobin electrophoresis shows a slight increase in 
hemoglobin A2. Coexisting iron deficiency anemia can lower hemoglobin 
A2 levels. 
As in mild alpha thalassemia, physicians often mistake the small red blood 
cells of the person with beta thalassemia minor as a sign of iron-deficiency 
anemia and incorrectly prescribe iron supplements. 
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b) Thallasemia intermedia: 
In this condition the lack of beta protein in the hemoglobin is great enough 
to cause a moderately severe anemia and significant health problems, 
including bone deformities and enlargement of the spleen. However, there 
is a wide range in the clinical severity of this condition, and the borderline 
between thalassemia intermedia and the most severe form, thalassemia 
major, can be confusing. The deciding factor seems to be the amount of 
blood transfusions required by the patient. The more dependent the patient 
is on blood transfusions, the more likely he or she is to be classified as 
thalassemia major. Generally speaking, patients with thalassemia 
intermedia need blood transfusions to improve their quality of life, but not 
in orderto survive. 
c) Thalassemia Major or Cooley’s Anemia: 
Beta- thalassemia major (also known as Cooley anemia) is the 
homozygous form. This is the most severe form of beta thalassemia in 
which the complete lack of beta protein in the hemoglobin causes a life-
threatening anemia that requires regular blood transfusions and extensive 
ongoing medical care. These extensive, lifelong blood transfusions lead to 
iron-overload which must be treated with chelation therapy to prevent 
early death from organ failure. 
Sign & Symptom: 
Thalassemia can cause complications, including iron overload, bone deformities, and 
cardiovascular illness. 
 Iron overload: People with thalassemia can get an overload of iron in their 
bodies, either from the disease itself or from frequent blood transfusions. Too 
much iron can result in damage to the heart, liver, and endocrine system, 
which includes glands that produce hormones that regulate processes 
throughout the body. The damage is characterized by excessive deposits of 
iron. Without adequate iron chelation therapy, almost all patients with beta-
thalassemia accumulate potentially fatal iron levels.33 
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 Infection: People with thalassemia have an increased risk of infection. This is 
especially true if the spleen has been removed.34 
 Bone deformities: Thalassemia can make the bone marrow expand, which 
causes bones to widen. This can result in abnormal bone structure, especially 
in the face and skull. Bone marrow expansion also makes bones thin and 
brittle, increasing the risk of broken bones.35 
 Enlarged spleen: The spleen aids in fighting infection and filters unwanted 
material, such as old or damaged blood cells. Thalassemia is often 
accompanied by the destruction of a large number of red blood cells and the 
task of removing these cells causes the spleen to enlarge. Splenomegaly can 
make anemia worse, and it can reduce the life of transfused red blood cells. 
Severe enlargement of the spleen may necessitate its removal.  
 Slowed growth rates: Anemia can cause a child's growth to slow. Puberty also 
may be delayed in children with thalassemia. 
 Heart problems: Diseases, such as congestive heart failure and abnormal heart 
rhythms, may be associated with severe thalassemia.36 
 
Management 
Mild thalassemia: people with thalassemia traits do not require medical or follow-up 
care after the initial diagnosis is made.37 People with β-thalassemia trait should be 
warned that their condition can be misdiagnosed as the more common iron deficiency 
anemia. They should avoid routine use of iron supplements; iron deficiency can 
develop, though, during pregnancy or from chronic bleeding.38 Counseling is 
indicated in all persons with genetic disorders, especially when the family is at risk of 
a severe form of disease that may be prevented.39 
Severe thalassemia: People with severe thalassemia require medical treatment. A 
blood transfusion regimen was the first measure effective in prolonging life.37 
Medications 
Multiple blood transfusions can result in iron overload. The iron overload related to 
thalassemia may be treated by chelation therapy with the medications 
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deferoxamine, deferiprone, or deferasirox.40These treatments have resulted in 
improved life expectancy in those with thalassemia major.40 
Carrier detection 
 A screening policy exists in Cyprus to reduce the incidence of thalassemia, 
which, since the program's implementation in the 1970s (which also includes 
prenatal screening and abortion), has reduced the number of children born 
with the hereditary blood disease from one of every 158 births to almost 
zero.41 
 In Iran as a premarital screening, the man's red cell indices are checked first, if 
he has microcytosis (mean cell hemoglobin < 27 pg or mean red cell volume < 
80 fl), the woman is tested. When both are microcytic, their hemoglobin 
A2 concentrations are measured. If both have a concentration above 3.5% 
(diagnostic of thalassemia trait) they are referred to the local designated health 
post for genetic counseling.42 
 Large scale awareness campaigns are being organized in India both by 
government and non-government organizations in favor of voluntary 
premarital screening to detect carriers of thalassemia and marriage between 
both carriers are strongly discouraged.  
Bone marrow transplant 
Bone marrow transplantation may offer the possibility of a cure in young people who 
have an HLA-matched donor.43Success rates have been in the 80–90% 
range.43 Mortality from the procedure is about 3%.44 There are no randomized 
controlled trials which have tested the safety and efficacy of non-identical donor bone 
marrow transplantation in persons with β- thallassemia who are dependent on blood 
transfusion.45 
If the person does not have an HLA-matched compatible donor, another method 
called bone marrow transplantation (BMT) from haploidentical mother to child 
(mismatched donor) may be used. In a study of 31 people, the thalassemia-free 
survival rate 70%, rejection 23%, and mortality 7%. The best results are with very 
young people.46 
 
 24 
 
1.2.2.3  Anemia of chronic disease: 
Anemia of chronic disease can be caused by chronic infections or inflammatory 
processes. Increased levels of cytokines cause a decrease in erythropoietin production, 
a decreased response to erythropoietin, and interference with iron 
metabolism. Although anemia of chronic disease is usually normocytic, about one 
fourth to one third of cases are mildly microcytic. The anemia is usually mild and not 
progressive. Additionally, although serum iron levels are decreased in anemia of 
chronic disease (similar to iron deficiency anemia), ferritin levels are increased 
because ferritin is an acute phase reactant. 33 
1.2.3 Diagnostic Strategy 15 
Serum ferritin measurement is the first laboratory test recommended in the evaluation 
of microcytosis. Low ferritin levels suggest iron deficiency. Once a presumptive 
diagnosis of iron deficiency anemia has been made, an underlying source for the 
deficiency should be determined. Iron deficiency anemia in adults is presumed to be 
caused by blood loss; the most common source of bleeding is the gastrointestinal 
tract. The possibility of gastrointestinal malignancy must be considered. If the serum 
ferritin level is not initially low, further evaluation should include total iron-binding 
capacity, transferrin saturation level, serum iron level, and possibly hemoglobin 
electrophoresis. Anemia of chronic disease is suggested with low iron levels and 
decreased total iron-binding capacity. Patients with beta-thalassemia trait usually have 
elevated levels of hemoglobin A2. 
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Diagnosing the Cause of Microcytosis:15 
 
Figure 1.3 : suggested algorithm for diagnosing the cause of microcytosis in adults.  
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1.2.4 Laboratory Evaluation17 
Laboratory tests that may help in differentiating the cause of microcytosis include red 
blood cell distribution width using the CBC, serum iron levels, serum ferritin levels, 
total iron-binding capacity (TIBC), transferrin saturation, hemoglobin electrophoresis, 
and occasionally  reticulocyte blood count , recently included reticulocyte hemoglobin 
equivalent and peripheral blood smears.    
CBC47 :   
 The complete blood count (CBC) is often used as a broad screening test to 
determine an individual's general health status and detect a wide range of 
disorders, including anemia, infection and leukemia.  
 Parameters of particular interest through CBC was listed below:    
Hb, RBC, Hct, MCV, MCH, RDW–standard deviation (SD), RDW–coefficient 
of variation (CV), reticulocytes (%), Ret–hemoglobin equivalent (RET - He). 
 Red blood cell (RBC) count is a count of the actual number of red 
blood cells in a person's sample of blood.  
 Hemoglobin measures the total amount of the oxygen-carrying protein 
in the blood, which generally reflects the number of red blood cells in 
the blood. 
 Hematocrit measures the percentage of a person's total blood volume 
that consists of red blood cells. 
 Red blood cell indices are calculations that provide information on the 
physical characteristics of the RBCs: 
I. Mean corpuscular volume (MCV) is a measurement of the 
average size of a single red blood cell. 
II. Mean corpuscular hemoglobin (MCH) is a calculation of the 
average amount of hemoglobin inside a single red blood cell. 
III. Mean corpuscular hemoglobin concentration (MCHC) is a 
calculation of the average concentration of hemoglobin inside a 
single red blood cell. 
IV. Red cell distribution width (RDW) is a calculation of the 
variation in the size of RBCs. 
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Figure 1.4 :  Red Blood Cells 
 
 Ret Hb Equivalent48:   
 Measuring the haemoglobin content of reticulocytes, RET-He or 
reticulocyte haemoglobin equivalent, is a way of diagnosing and 
monitoring iron deficiency anaemia.  
 The reference range for RET-He is approximately 28-35 pg [~1.77-
2.22 fmol], below 28 pg [1.77 fmol] is considered iron deficient. 
 Benefit: The clinical usefulness of the Ret-He parameter has been 
proven and it is now an established parameter in advanced 
haematological analysis. “Reticulocyte haemoglobin content” is 
recommended in nephrology guidelines such as the European Best 
Practice Guidelines (EBPG), National Kidney Foundation Kidney 
Disease Outcome Quality Initiative (NKF KDOQI) 
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Ret-He: 
 Indicates the trend of the current iron status. 
 RET-He and RET# together let clinicians draw conclusions on both the quality 
and quantity of the young RBC fraction. 
 Is an early marker for disease - earlier than clinical chemistry markers! 
 Fast and inexpensive! 
 RET-He is used for monitoring erythropoietin (EPO) and iron therapy. If the 
value increases it indicates the therapy is having a positive effect. 
 
 
 
                                 Figure 1.5 : Collection of blood in K2EDTA vial 
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Normal Results of CBC: 49 
Blood counts may vary with altitude. In general, normal results are: 
Red blood cell (RBC) count  
Men: 4.5-5.5 million RBCs per microliter (mcL) or 4.5-5.5 x 1012/liter (L) 
Women: 4.0-5.0 million RBCs per mcL or 4.0-5.0 x 1012/L 
 
Hematocrit (HCT)   
Men: 42%-52% or 0.42-0.52 volume fraction 
Women: 36%-48% or 0.36-0.48 volume fraction 
 
Hemoglobin (Hb)  
Men: 13-18 grams per deciliter (g/dL)  
Women: 11.5-16.5 g/dL 
 In general, a normal hemoglobin level is about one-third the value of the 
hematocrit. 
Red blood cell indices 
Mean corpuscular volume (MCV)-Adults: 84-96 femtoliters (fL) 
Mean corpuscular hemoglobin (MCH)-Adults: 
27-32 picograms (pg)per 
cell 
Mean corpuscular hemoglobin concentration 
(MCHC)-Adults: 
32-36 grams per deciliter 
(g/dL) 
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Red cell distribution width (RDW)   
Normal: 11.5%-14.5% 
 
Reticulocyte count 
Normal: 0.5%-1.5%. 
                                   
Ret Hb Equivalent 
Normal: 28-35 pg 
 
 
Ferritin15: 
 Ferritin is a complex of iron and the binding protein apoferritin.  Ferritin 
reflects true iron stores and is not susceptible to the short-term variations that 
occur with serum iron levels and TIBC. However, ferritin is also an acute 
phase reactant and can be elevated with liver disease, malignancy, and chronic 
renal disease. Iron deficiency anemia is likely if the ferritin level is less than 
15 ng per mL (15 mcg per L) in an otherwise healthy person, or less than 50 
ng mL (50 mcg per L) in a person with an underlying source of chronic 
inflammation. Iron deficiency can usually be excluded when the ferritin level 
is greater than 100 ng per mL (100 mcg per L).  
 
 
 
 31 
 
Table: 1.2 Laboratory Tests in the Differential Diagnosis of Microcytosis50 
TEST 
SUGGESTED DIAGNOSIS 
IRON 
DEFICIENCY 
ANEMIA THALASSEMIA 
ANEMIA 
OF 
CHRONIC 
DISEASE 
SIDEROBLASTIC 
ANEMIA 
Serum 
ferritin 
level 
Decreased Increased Normal 
to 
increased 
Normal to 
increased 
Red blood 
cell 
distribution 
width 
Increased Normal to 
increased 
Normal Increased 
Serum iron 
level 
Decreased Normal to 
increased 
Normal 
to 
decreased 
Normal to 
increased 
Total iron-
binding 
capacity 
Increased Normal Slightly 
decreased 
Normal 
     
Hemoglobin Electrophoresis51 
Hemoglobin electrophoresis test is a blood test done to check the different types 
of hemoglobin in the blood  
 The electrophoresis process takes advantage of the fact that hemoglobin types 
have different electrical charges. During electrophoresis, an electrical current is 
passed through the hemoglobin in a blood sample, which causes the 
hemoglobin types to separate at different rates and form bands. By comparing 
the pattern formed with that of a normal blood sample, doctors can see the 
types and quantities of hemoglobin present in the blood sample. 
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The most common types of normal hemoglobin are: 
 Hemoglobin A. This is the most common type of hemoglobin found normally 
in adults. Some diseases, such as severe forms ofthalassemia, may cause 
hemoglobin A levels to be low and hemoglobin F levels to be high. 
 Hemoglobin F (fetal hemoglobin). This type is normally found 
infetuses and newborn babies. Hemoglobin F is replaced by hemoglobin A 
(adult hemoglobin) shortly after birth; only very small amounts of hemoglobin 
F are made after birth. Some diseases, such as sickle cell disease, aplastic 
anemia, and leukemia, have abnormal types of hemoglobin and higher amounts 
of hemoglobin F. 
 Hemoglobin A2. This is a normal type of hemoglobin found in small amounts 
in adults. 
 
Hemoglobin electrophoresis  
Hemoglobin A1: 96.5%-98.5% of total hemoglobin or 0.96-0.985 mass fraction 
Hemoglobin A2: 1.5%-3.5% of total hemoglobin or 0.015-0.035 mass fraction 
Hemoglobin F: 0%-1% of total hemoglobin or 0-0.01 mass fraction 
 
An abnormal amount of normal hemoglobin or an abnormal type of hemoglobin in the 
blood may mean that a disease is present. Abnormal hemoglobin types may be present 
without any other symptoms, may cause mild diseases that do not have symptoms, or 
cause diseases that can be life-threatening. 
After describing the diagnostic strategy of microcytosis, we can say that electronic 
cell counters have been used to determine red cell indices as a first indicator of β-TT 
and IDA. The purpose of using indices to discriminate anemia is to detect subjects 
who have a high probability of requiring appropriate follow-up and to reduce 
unnecessary investigative costs. Since 1970, a number of complete blood count 
indices have been proposed as simple, less time consuming and inexpensive tools to 
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determine whether a blood sample is more suggestive of β-TT or IDA52. Most of these 
articles include adults but very few data are available on children.  
Previously, many discrimination indices have been reported using red blood cell 
(RBC) indices obtained by automated blood count. Many authors have calculated the 
sensitivity and specificity of these  indices in the distinction between IDA and BTT . 
They proposed that the diagnosis could be established without having to resort to the 
more time-consuming methods such as transferrin saturation (TS), ferritin and 
hemoglobin A2 (HbA2) levels. But a definitive diagnosis of  β-TT and IDA is based 
on the result of HbA2 electrophoresis, serum iron levels, and a ferritin calculation 
53. 
However, none of these indices showed a sensitivity and specificity of 100% in 
prediction of IDA and BTT. Some showed considerable sensitivity for IDA or BTT, 
but not specificity54.  
 
It was noted that none of them was entirely satisfactory and none of these 
formulations was superior to RBC value obtained from automated analyzers in 
diagnosing these two conditions 26.So these indices are not very important today given 
the availability of Hb electrophoresis.A question arises that how many of physians  
memorize these formulas and use them in their daily practice in crowded outpatient 
settings. However, we do consider MCV and RBC which is easy to calculate. How 
many of them would be brave enough to not study Hb electrophoresis in a woman 
with mild hypochromic anemia unresponsive to iron therapy who was planning a 
pregnancy.Finally we can say that total body iron status, serum ferritin calculation and 
HbA2 level should be obtained for accurate diagnosis of IDA and BTT until more 
efficient tools are developed.  
 
1.3 Aims and Objectives 
a) This study provides a diagnostic strategy of microcytic hypochromic anaemia 
specially IDA & BTT. 
b) The purpose of this study was to explore the diagnostic value of complete blood 
count (CBC) along with a new parameter (RET – He) in diagnosing BTT & IDA.  
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2.1. Materials : 
2.1.1 Chemicals :  
I) For CBC :  
 Cell pack DCL 
 Cell pack DFL 
 Sulfolyzer 
 Lyser cell WNR 
 Lyser cell WDF 
 Flurocell WNR 
 Flurocell WDF 
 Flurocell RET 
 Cell clean 
 XN Check  
II) For Hemoglobin Electrophoresis : 
 Hemoglobin buffer 
 Hemolysing solution 
 Wash solution 
 Capi clean 
 Distilled water 
 Normal Hb A2 Control 
 
2 . Materials and Methods 
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2.1.2 Euipments :  
 Sysmex XN 1000  
 Capillarys 2 Sebia 
 Architect i1000SR immunoassay 
 Centrifuge Machine 
 Lab Rotator 
 Rubber tit 
 Pasteur pipette 
 Micropipette 
 Sample rack 
 
2.2 Methods : 
            2.2.1. Selection criteria : 
 No of cases :            210 adult subjects 
 Age:                         18 yrs – 55 yrs 
 Sex:                          Both male and female 
 
2.2.2  Exclusion criteria : 
 Subject who received transfusion within 3 months 
 Subject who receive iron therapy 
 Age: subject below 18 yrs 
 Hb level:  <8.0 (gm/dl) 
 Other abnormal Hb variant 
 
2.2.3  Area of study :  
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Department of Clinical Hematology 
Clinical laboratories 
Icddr,b, Mohakhali, Dhaka 
 
2.2.4 Period of Study : 
 January  2015 to October  2015 
 
2.2.5 Following procedures were adopted : 
 250 adult subjects were selected irrespective of  sex. 
 The samples were obtained during the course of routine analysis. All 
samples were collected aseptically in specimen reception unit. Care 
was taken to avoid insufficient or excess anticoagulant, inadequate 
mixing of blood with anticoagulant, subject or specimen identification 
error and delay in transit to the laboratory. 
 Routinely venous blood samples were collected from all subjects in 
k2EDTA anticoagulated tube. It was used for the investigation of 
microcytosis  for this study through CBC. 
 All blood samples were analysed within 4 hours after collection. 
 With the advent of automation  in haematology, the first line of 
screening of IDA and thalassemia is possible through Complete Blood 
Count (CBC). At first for primary selection of subject, CBC was 
obtained for all samples. Samples were run on automated hematology 
analyser (sysmex XN-1000, Japan) on the day of collection (day 0) to 
avoid any changes in mean corpuscular volume (MCV) that may occur 
on sample storage in EDTA.  
 Automated hematoly analyzer XN 1000 perform analysis based on the 
hydro dynamic focusing method, flow cytometry, semi conductor 
assay and SLS hemoglobin method. 
 Parameters of particular interest were hemoglobin, RBC, Hct, MCV, 
MCH, RDW–standard deviation (SD), RDW–coefficient of variation 
(CV),  reticulocytes (%), Ret–hemoglobin equivalent (He). 
 The subjects with Hb value <8.0 g/dl (n = 21)  were excluded in order 
to not confuse more severe IDA with BTT. 
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 We investigated for microcytosis and once microcytosis (defined as 
MCV less than 80 fl)    is detected in samples, the following were 
performed: 
i. Measuring  HbA2 level by capillary zone electrophoresis 
(Capillary 2 Sebia) .  
ii. Diagnosis of BTT was made on the basis of  HbA2 levels more 
than 3.5%. 
iii. The subjects with abnormal Hb variant (n = 19) were excluded 
from the study. 
iv. For microcytic samples with normal Hb typing  by capillary 
electrophoresis and HbA2 level less than 3.5%,  Iron deficiency 
anaemia was suspected. With proper consent taking from those 
suspected subjects, clotted blood sample was collected for 
measuring serum ferritin level by architect i1000SR 
immunoassay. Diagnosis of IDA was made on the basis of 
ferritin value lower than 15 ng/ml . 
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3.1 
After Analyzing CBC, according to MCV, selected blood samples were 
grouped into the following : 
Group I:  the normal MCV group (MCV > 80fl). 
Group II: the microcytosis group (MCV < 80fl). 
According to Hb electrophoresis results and serum ferritin level, group II was 
subdivided into the following : 
Group IIA : the IDA group 
Group IIB : the BTT group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Results 
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3.2 Observation:   
Age ranged from 18 to 55 years ([Table 3.1]). The study included 119 female 
and 91 male participants ([Table 3.1]). 
  
TABLE 3.1 
 
Table 3.1:  Shows comparison 
between groups I, IIA, and IIB 
regarding age. 
 
 
TABLE 3.2 
 
Table 3.2 : Shows comparison 
between groups I, IIA, and IIB 
regarding sex. 
 
 
 
 
In this study, BTT represents 16% (n = 34) from total number of subjects, whereas 
IDA represents 16.6% (n = 35) ([Table 3.2]). 
 
 
With respect to RBCs count, an elevated RBC count was detected  in group IIB ( 5.48 
± 0.69 × 10 6 / mm 3) than group group I (4.85 ± 0.44 × 10 6 /mm 3 ) and IIA (4.66 ± 
0.48 × 10 6 /mm3) .([Table 3.3]). 
TABLE 3.3 
 
Table : 3. 3 Comparison 
between groups I, IIA, 
and IIB regarding RBC 
concentration. 
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With respect to Hb level, boh  group IIA (9.31 ±  0.81 g/dl) and IIB (10.58 ± 1.35 
g/dl) showed reduced Hb concentration in contrast to group I (13.55 ± 1.41 g/dl). 
([Table 3.4]) 
 
TABLE 3.4 
 
Table : 3. 4 Comparison 
between groups I, IIA, and 
IIB regarding Hb 
concentration. 
 
 
 
 
 
 
With respect to hematocrit value, boh  group IIA (31.69 ± 2.6l%) and IIB (34.43 ± 
4.35%) showed  reduced Hct  concentration in contrast to group I (41.08 ± 3.58%). 
([Table 3.5]) 
 
TABLE 3.5 
 
Table : 3.5 Comparison 
between groups I, IIA, and 
IIB regarding HCT value  
 
 
 
Red blood cell distribution width (RDW - CV) was the highest in group IIA followed 
by group IIB and then group I ( 19.50  ± 3.43 %, 17.29  ± 2.13 %, 13.25  ± 2.11 % 
respectively)  ([Table 3.6]). 
 
TABLE 3.6 
 
Table  :3. 6 Comparison 
between groups I, IIA, and 
IIB regarding RDW. 
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The least MCV values were seen in group IIB (63.02  ± 3.34 fl ) compared with the 
group IIA (67.84 ± 4.40 fl). ([Table 3.7] 
TABLE 3.7 
 
Table : 3. 7 Comparison 
between groups IIA and IIB 
regarding MCV  
 
 
 
With respect to MCH  level, boh  group IIA (20.03 ± 2.04 pg ) and IIB (18.84 ± 1.38 
pg ) showed  reduced  MCH  concentration in contrast to group I (27.84 ± 1.61 pg). 
([Table 3.8]).  
 
TABLE 3. 8 
 
Table : 3.8 Comparison 
between groups I, IIA, 
and IIB regarding MCH 
concentration . 
 
 
The least RET -He values were seen in group  IIA (20.2  ±  3.34 pg) and IIB (20.31 ± 
1.55pg) compared with the group I (29.44  ± 2.13 pg). ([Table 3.9]) 
TABLE 3.9 
 
Table 3.9 
Comparison 
between groups I, 
IIA, and IIB 
regarding  RET-He 
concentration 
 
Raised Hb A2 level was seen in group IIB (4.89  ±  0.58%) compared with group IIA 
(1.94  ±  0.18%) . ([Table 3.10]) 
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TABLE 3.10 
HbA2 Number Mean ±SD Max min 
I 141 2.61 0.20 3.1 2.2 
IIA 35 1.94 0.18 2.1 1.4 
IIB 34 4.89 0.58 5.9 3.6 
  210         
 
Table 3.10 
Comparison 
between groups I, 
IIA, and IIB 
regarding  Hb A2 
concentration  
 
 
 
 
Electrogram of Group I, Group IIA and Group IIB by Capillarys 2 Sebia 
 
Figure 1.6: Electrogram of Group I(Normal study) 
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Figure 1.7: Electrogram of Group IIA(Low HbA2 level) 
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Figure 1.8: Electrogram of Group IIB(Beta-thalassemia trait or carrier) 
 
Ferritin level of group IIA (5.63  ±  2.70 ng/ml) suggests  iron deficiency anaemia. 
TABLE 3.11 
Ferritin Number Mean ±SD Max min 
IIA 35 5.63 2.70 12.3 1.72 
           
 
Table 3.11 
Biochemical 
data of group 
IIA regarding  
Ferritin level  
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IDA and β-thalassemia minor are recognized as the most important causes of 
hypochromia and microcytosis55,56. With respect to high prevalence of anemia among 
young couple, simple 
and easy diagnosis of TT and IDA is crucial. Determination of cell blood count 
(CBC) by electroniccell counter is a first step in the diagnosis of TT and IDA in mass 
screening strategy. Both anemias are usually present with microcytosis mean 
corpuscular volume (MCV<80) and hypochromia mean corpuscular hemoglobin 
(MCH <27). the cell-count-based indices are easily available and reliable methods for 
detecting β-TT & IDA. Cell-count-based parameters particularly the MCV and RBC 
counts  have good discrimination ability in diagnosing β-TT & IDA. 
 
Of the 210 samples investigated in our study, microcytic samples were 69 samples 
representing 33.0% in all selected study subject. The reported prevalence of 
microcytosis in similar studies ranged from 5.4 to 45% according to the ethnic 
background of the study population. 
 
In our study, BTT was found in 34 samples representing 16% of all 210 tested 
samples and 49.2% of all 69 microcytic samples. To avoid much more expensive, 
time-consuming, and complicated procedures for diagnosing these  two disorders, 
researchers attempt to use either RBC indices such as MCV, MCH, and RDW, or 
formulas derived from these indices. This process helps to select appropriate  
individuals for more detailed examination. 
 
Comparable results with differences related to ethnic backgrounds of the studied 
groups were reported. In the Yemeni study by Al-Nood57, BTT was detected in 31 
patients representing 4.43% of all tested samples and 30% of microcytic samples. In 
an Indian study, Tiwari et al. 58studied the prevalence of BTT in microcytic blood 
donor samples and it was 36% of all microcytic donor samples (18 from 50 
microcytic samples). However, the study by Tiwari et al. 58involved both deferred and 
actual blood donors on different ethnic group at Blood Bank of Uttarakhand, 
4. Discussion 
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Dehradun, Uttarakhand, India. In the study by Ali et al.59, of the 181 patients studied, 
diagnosis of BTT was made in 10 patients (5.5%). This study was conducted in  
general Pakistani population. 
 
In the study by Rahim et al.60, totally 323 individuals (173 children and 150 adults) 
with microcytosis were investigated at Research Center of Thalassemia & 
Hemoglobinopathies, Ahwaz, Iran. Of the 323 patients, 153 (59 children and 94 
adults) were diagnosed to have BTT representing 47.36% of microcytic samples. 
Comparing another study in India by Parthasarathy61 who searched for BTT in 200 
adult samples with microcytosis but not in healthy blood donors, BTT was found in 
39 samples representing 19.5% of the total 200 microcytic samples. Parthasarathy 
used 80 fl as a cutoff for microcytosis in their study, which is similar what we used  
and could have attributed to their lower results. 
 
Much lower prevalence of β-thalassemia minor was detected in other previous reports. 
Bolaman et al.62 screened a total of 14200 couples before their marriage for BTT in 
Denzili, Turkey and found that carriers for b-thalassemia represent 2.2%. This was 
less than that found in our study, may be due to involvement of much more larger  
scale of population of different ethnic origin. 
 
In our study, 35 of the 210 samples had IDA representing 16.66% of all tested 
samples and 50.7% of the 69 microcytic samples. 
 
Another study by Tiwari et al.58who found IDA in 26 donors representing 2.81% of 
all tested samples and 52% of 50 microcytic samples. 
In the study by Al-Nood 57 , iron deficiency accounted for only a small proportion 
(12/699 patients) representing 1.72% of all tested samples and 11.65% of microcytic 
samples, but he investigated samples in outpatient clinic not in blood donors. 
 
Higher prevalence rate of IDA was detected by Al-Dabbagh et al.63 who found that 
16% of the studied Emirati healthy women had IDA (33/204) and 65.0% had ferritin 
values of less than 30.0 μg/l (133/204). Similarly, Parthasarathy 61 found IDA in 120 
samples representing 60% of their study population. 
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IDA is well known to be the most common cause of microcytic anemia especially in 
underdeveloped countries. In our study, the prevalence of IDA was higher than that of 
BTT among our study population (16.6% and 16 %, respectively).  
In addition, our IDA group showed a highly significant reduction in their mean Hb 
levels  when compared with the normocytic group, also the mean Hb of the BTT 
group showed highly  significant difference compared with the normocytic group. 
This indicates that the BTT group  and IDA group had lower Hb concentration.  
In our study, a lower mean value of MCV for the BTT group than the IDA group was 
detected with highly significant statistical difference.  
 
RBCs count showed a highly significant elevation in BTT than in IDA and also 
showed a highly significant elevation than in the normal group . previous study 
reported that RBCs count was the only parameter that had both sensitivity and 
specificity of 100% for differentiating both IDA and BTT. Tiwari et al. 58 also found 
that RBC count is the only parameter that had both sensitivity and specificity more 
than 80%. This difference may be due to involvement of deferred anemic donors in  
their study. 
 
According to our study, RDW showed a highly significant difference between BTT 
and IDA . The highest RDW was found in IDA followed by the BTT reflecting more 
anisocytosis in IDA than BTT. Both Rahim et al. 60 and Parthasarathy 61 also found 
that RDW was higher in IDA than in BTT patients. 
 
In previouly reportedmany study, the cutoff values of MCV 73fl or less, RBC count 
above 5.47 × 10 6 /mm 3 , and RDW 14.5% or less were suggested to be associated 
with a high probability of BTT. 
 
Controversy continues regarding the ideal red cell indices and their cutoff values for 
differentiating BTT and IDA. Kotwal et al. 64 conducted a study with 640 adult 
patients with microcytosis (MCV<80 fl), plotting receiver operator characteristic 
curves and recalculating the cutoff values for the Indian setting. The cutoff values of 
MCV less than 76 fl, RBC count at least 4.9 × 10 12 /l, and RDW 18% or less were 
suggested to be associated with a high probability of BTT. However, 
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Parthasarathy61in India concluded that cutoff values of MCV below 76 fl, RBC count 
at least 4.9 × 10 6 /mm 3 , and RDW 18% or less were suggested to be associated with 
a high probability of BTT. Another Indian study 65 had cutoff values of MCV 78.0 fl 
or less, MCH 28 pg or less, and HbA 2 more than 3.8% for BTT diagnosis. 
 
In the present study, the RBC count and MCV have greater sensitivity than RDW. 
Shalev et al.66reported that the combination of a high RBC count and low MCV is 
characteristic of BTT. It has been suggested that the RBC count is the most efficient 
single test for differentiating BTT and IDA 64 66 67. Other studies showed superiority 
of RDW, followed by the RBC count and MCV in differentiating IDA and BTT68 . 
Therefore, we think a combination of MCV, RDW, and the RBC count is more 
effective for identifying BTT and differentiating it from other nonthalassemic 
microcytosis; however, it should be noted that patients with BTT and concomitant 
iron, vitamin B 12 , or folic acid deficiency, and double heterozygous dβ-thalassemics 
can have an elevated RDW 71,69,70. Concomitant nutritional deficiency can also alter 
HbA 2 levels in BTT. Microcytosis accompanied by a high RBC count and normal 
RDW is suggestive of BTT. 
 
In previous study measurement of hemoglobin in reticulocytes has proved useful for 
the diagnosis and follow-up of IDA 56, while its use in hemoglobinopathies has been 
less extensively elaborated57-61. In our study the least RET -He values were seen in 
IDA and BTT compared with the normal group .  
These automated red cell parameters are routinely examined and offer a rapid and 
reliable method for BTT &IDA screening. Adequate utilization of these parameters 
can facilitate Primary identification of the majority of BTT & IDA cases at no 
additional cost to the healthcare system. Identifying BTT carriers and counseling them 
about the genetic implications of marrying another carrier is the most effective 
method for preventing β-thalassemia major. 
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Iron-deficiency anaemia, is the most common nutritional deficiency worldwide. This 
is a common health problem in rural women and young children of Bangladesh. The 
anaemia prevention and control strategies have focused on correcting this deficiency 
by routine iron supplementation. 
Moreover, a thalassemic child and its family undergoes through a socio-economic 
strain in whole community. In thalassemia prevalent developing countries, carrier 
screening programs were successful in increasing the awareness about thalassemia 
among general mass as prevention is better than cure. The screening of thalassemia 
carriers in endemic areas remains a daily challenge for laboratory professionals. 
However, while Bangladesh is situated in a thalassemia prone region, hence it is 
imperative to consider thalassemia as an important health issue in this country. So the 
most effective approach to reduce the burden of the society and reduce disease 
incidence is implementation of carrier screening programmes offering genetic 
counselling and family screening, prenatal diagnosis and selective termination of 
affected fetuses.  
 As ß thalassemia minor and IDA are two common microcytic anemias, we conclude 
that genetic counseling for identification of thalassemia carriers in order to prevent the 
birth of thalassemia patients, differentiating BTT from IDA is warranted because the 
thalassemia heterozygote should not be given iron in a vain attempt to normalize 
MCV.  
 
Previously reported discrimination indices using red blood cell (RBC) indices was not 
entirely satisfactory in diagnosing between these conditions. The above-described 
diagnosing system is aimed at screening for thalassemia & IDA in samples for which 
full blood count parameters have been technically and clinically validated prior to the 
interpretive process. Its main aim is to focus attention and efforts on those samples 
requiring further investigation for a complete diagnosis.The implementation of a 
system such as the one we have described will introduce an accurate differential 
diagnosis of IDA and BTT. Ferritin calculation and HbA2 level should be obtained 
for accurate differential diagnosis of IDA and BTT until more efficient tools are 
developed.  
 Concluding remarks 
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